Mergers & Acquisitions ·
Senti Biosciences completes merger with Celadon SPV, divesting core business and issuing $2.5M equity
SNTISenti Biosciences Holdings, Inc.
On October 21, 2026, Senti Biosciences Holdings completed a merger with ST NewCo Limited (f/k/a Celadon Partners SPV 35 Limited), resulting in the divestiture of its entire ownership interest in Midco and Opco. Shareholders received Contingent Value Rights entitling them to up to $60 million in milestone payments for SENTI-202, including $10 million upon FDA BLA acceptance, $20 million upon approval, and $30 million if net sales exceed $200 million. The company also issued 7,309,941 shares to an affiliate of Celadon Partners for approximately $2.5 million in proceeds. Additionally, the company forced the exchange of $16 million in Senior Secured Convertible Notes into common stock at $0.342 per share. Senti Biosciences operates as a biotechnology company developing cell therapies and immunotherapies.